GlassScriptPhysician profile
Tasha M Chatman
NPI 1033726278
$3,553.15
in general payments reported to CMS, 2019-2025
21 companies · $968 in 2025
The $968 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $361 · 2022: $1,135 · 2023: $468 · 2024: $622 · 2025: $968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,057.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,057.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $568.60 | 2022-2025 | |
| Alnylam Pharmaceuticals INC. | $271.91 | 2021-2025 | Onpattro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.00 | 2025 | Ofev |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $247.76 | 2022-2025 | Xifaxan |
| Novo Nordisk INC | $246.87 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $220.53 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $146.20 | 2024 | Iqirvo |
| Kowa Pharmaceuticals America, INC. | $125.00 | 2025 | Zoryve |
| Amgen INC. | $125.00 | 2023 | Repatha |
| Grt US Holding, INC. | $125.00 | 2022 | |
| Argenx US, INC. | $124.99 | 2024 | Vyvgart |
| Redhill Biopharma INC. | $124.99 | 2022 | |
| Edwards Lifesciences Corporation | $124.97 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Intercept Pharmaceuticals, INC. | $122.52 | 2022 | |
| Sanofi-Aventis U.S. LLC | $121.83 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $117.06 | 2021 | |
| Abbott Laboratories | $114.79 | 2023 | Freestyle Libre 3 |
| Corcept Therapeutics | $102.80 | 2023 | Korlym |
| Axsome Therapeutics, INC. | $100.69 | 2025 | Auvelity |
| Springworks Therapeutics, INC. | $94.98 | 2025 | Gomekli |
| Scynexis, INC. | $76.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tasha Chatman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.